{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000019","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.652224+00:00","generated_at":"2026-06-18T17:23:31.296927+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AnaptysBio reports FY2022 net loss $128.7M; cash $584.2M; initiates Phase 2b trials for rosnilimab and ANB032","bullets":["Net loss for Q4 2022 was $26.4M ($0.93 per share); full year net loss $128.7M ($4.57 per share), compared to $57.8M in 2021.","Cash, cash equivalents and investments totaled $584.2M as of Dec 31, 2022; cash runway through year-end 2026 reiterated.","Initiating global Phase 2b trial for rosnilimab (PD-1 agonist) in RA in Q3 2023; second Phase 2 trial in another indication by year-end 2023.","Initiating global Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis in Q2 2023; top-line data expected year-end 2024.","Board authorized $50M stock repurchase plan in January 2023, expiring Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000019","json":"https://secwatch.observer/filing/0001370053-23-000019.json","markdown":"https://secwatch.observer/filing/0001370053-23-000019.md","text":"https://secwatch.observer/filing/0001370053-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000019/0001370053-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000019/anab-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T17:23:31.296927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b19e0c8f0a4d7eaf2512b614073cccde7cd6f5c2","claim":"ANAPTYSBIO, INC reported financial results for the three months and year ended December 31, 2022.","evidence_excerpt":"On March 1, 2023, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000019/0001370053-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}